delas

View All

Therapeutics
Valeant’s asset-sale; Sanofi coughs up $19.8M; Sanofi’s Genzyme; India’s Alkem; GSK’s inhalers

Valeant's asset-sale woes continue as Stada, Mundipharma lowball iNova bids Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continue to demonstrate, getting there may not be so easy. The bids rolling in for Valeant’s Australian iNova subsidiary aren’t...

Find More